Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14655625 | Publishing Date : 03-Sep-2019 | No. of pages : 132
Detailed TOC of Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• The threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Biologics - Market size and forecast 2018-2023
• Small molecules - Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-202
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strong pipeline
• Increasing research funding
• Special drug designations
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche Ltd.
• PTC Therapeutics Inc.
• Santhera Pharmaceuticals
• Sarepta Therapeutics Inc.
• Wave Life Sciences Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global DMD therapeutics market pipeline: Overview
Exhibit 19: Global DMD therapeutics market pipeline: Snapshot
Exhibit 20: Type - Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 57: PTC Therapeutics Inc. - Vendor overview
Exhibit 58: PTC Therapeutics Inc. - Business segments
Exhibit 59: PTC Therapeutics Inc. - Organizational developments
Exhibit 60: PTC Therapeutics Inc. - Key offerings
Exhibit 61: PTC Therapeutics Inc. - Key customers
Exhibit 62: Santhera Pharmaceuticals - Vendor overview
Exhibit 63: Santhera Pharmaceuticals - Business segments
Exhibit 64: Santhera Pharmaceuticals - Organizational developments
Exhibit 65: Santhera Pharmaceuticals - Geographic focus
Exhibit 66: Santhera Pharmaceuticals - Key offerings
Exhibit 67: Santhera Pharmaceuticals - Key customers
Exhibit 68: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 69: Sarepta Therapeutics Inc. - Business segments
Exhibit 70: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 71: Sarepta Therapeutics Inc. - Geographic focus
Exhibit 72: Sarepta Therapeutics Inc. - Key offerings
Exhibit 73: Sarepta Therapeutics Inc. - Key customers
Exhibit 74: Wave Life Sciences Ltd. - Vendor overview
Exhibit 75: Wave Life Sciences Ltd. - Business segments
Exhibit 76: Wave Life Sciences Ltd. - Organizational developments
Exhibit 77: Wave Life Sciences Ltd. - Key offerings
Exhibit 78: Wave Life Sciences Ltd. - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Definition of market positioning of vendors